N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Left Ventricle Function
Primary: Left Ventricular Ejection Fraction (LVEF), Change From Baseline — 2.00; -3.25 Percent change
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
N/A N=22 InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's
Heart Diseases · Left Ventricular Dysfunction
Primary: Peak Vo2 — 33; 12.5 ml/kg/min
N/A N=16 Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction
Diastolic Dysfunction
Primary: Change in Left Ventricle Mean Diastolic Pressure — 3.3 mmHg
N/A N=446 The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
Chronic Heart Failure
Primary: Stroke-Free Survival Probability for 2 Years Post Implant — 55.4; 59.1 Probabillity — p=0.0110
N/A N=30 Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
Renal Dialysis · Hemodiafiltration · Diastolic Dysfunction
Primary: Left Ventricular Diastolic Function Category — 15; 15; 5; 5 Participants — p=0.06
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
N/A N=610 REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart Failure
Primary: Percentage of Patients Worsened for Clinical Composite Response — 21.5; 16 Percentage of participants worsened — p=0.10
N/A N=165 Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy
Congenital Heart Disease
Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
Phase 3 N=133 PUFAs and Left Ventricular Function in Heart Failure
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
N/A N=197 Model 4396 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants
Phase 4 N=229 The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
Hypertension · Diastolic Dysfunction
Primary: Change in Lateral Mitral Annular Myocardial Relaxation Velocity — 1.544; 1.476 cm/s
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Phase 2 N=122 Interventricular Delay of Lumax HF-T for Heart Failure
Congestive Heart Failure
Primary: Percentage of Subjects Classified as "Not Worsened" for Changes in the Minnesota Living With Heart Failure Questionnaire and Six-minute Walk Distance Between Periods of…
N/A N=523 Risk Stratification in Patients With Preserved Ejection Fraction
Myocardial Infarction
Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
N/A N=24 Noninvasive Neuromodulation to Reserve Diastolic Dysfunction
Heart Failure, Diastolic
Primary: Echocardiographic Markers of Diastolic Dysfunction — -21.2; -23.0 percent
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
N/A N=187 Predictors of Response to Biventricular Pacing in Heart Failure
Heart Failure, Wide QRS Complex
Primary: Minnesota For Living With Heart Failure Questionnaire — 31; 24 units on a scale
Phase 1 N=40 Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
Heart Failure
Primary: Safety of Single Ascending Doses of GGF2 Via an Assessment of the Toxicology Profile as Measured by Treatment Emergent Adverse Events (TEAEs) — 6; 4; 4; 2 participants
Phase 3 N=93 The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19
N/A N=28 Rhode Island Diastolic Dysfunction - Heart Failure
Heart Failure · Cardiovascular Disease
Primary: Change From Baseline in Oxygen Consumption During Maximal Bike Exercise — 14.45; 14.18 mL/kg/min — p=0.823
N/A N=20 Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
Ventricular Tachycardia
Primary: Number of Participants With Procedural Success — 8; 6 Participants